Specify a stock or a cryptocurrency in the search bar to get a summary
Ascelia Pharma AB (publ)
ACEAscelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden. Address: Hyllie Boulevard 34, Malmö, Sweden, 215 32
Analytics
WallStreet Target Price
101.61 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACE
Dividend Analytics ACE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACE
Stock Valuation ACE
Financials ACE
Results | 2019 | Dynamics |